Differences in clinical importance of Bcl-2 in breast cancer according to hormone receptors status or adjuvant endocrine therapy

ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia

(2013) C. J. Vandenberg et al.   BLOOD

Targeting BCL-2 with the BH3 Mimetic ABT-199 in Estrogen Receptor-Positive Breast Cancer

(2013) François Vaillant et al.   CANCER CELL

Bcl-2 expression predicts sensitivity to chemotherapy in breast cancer: a systematic review and meta-analysis

(2013) Dong Yang et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

(2013) Andrew J Souers et al.   NATURE MEDICINE

Prognostic significance of Bcl-2 in invasive mammary carcinomas: a comparative clinicopathologic study between “triple-negative” and non–“triple-negative” tumors

(2011) Kareem Tawfik et al.   HUMAN PATHOLOGY

Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737

(2011) S. R. Oakes et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received

(2010) S-J Dawson et al.   BRITISH JOURNAL OF CANCER

Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer

(2009) Grace M Callagy et al.   BMC CANCER

Clinical Importance of Estrogen Receptor-β Evaluation in Breast Cancer Patients Treated With Adjuvant Tamoxifen Therapy

(2008) Naoko Honma et al.   JOURNAL OF CLINICAL ONCOLOGY